Equity Components [Axis]
Corporate Capital [Member]
Additional Paid-in Capital [Member]
Common Stock [Member]
Retained Earnings [Member]
Sale of Stock [Axis]
IPO [Member]
Over-Allotment Option [Member]
Trading Activity [Axis]
Foreign Exchange [Member]
Plan Name [Axis]
Equity Incentive Plan 2021 - 2025 [Member]
Antidilutive Securities [Axis]
Warrant [Member]
Share-Based Payment Arrangement, Option [Member]
Statistical Measurement [Axis]
Maximum [Member]
Award Type [Axis]
Minimum [Member]
Long-Lived Tangible Asset [Axis]
Equipment And Furniture [Member]
Electronic Office Equipment [Member]
Leasehold Improvements [Member]
Related Party Transaction [Axis]
Research And Development Expense Related Party [Member]
Italian Revenue Agency [Member]
Title of Individual [Axis]
Directors and Officers [Member]
Balance Sheet Location [Axis]
Prepaid Expenses and Other Current Assets [Member]
Ownership [Axis]
Quota A [Member]
Quota B [Member]
Quota C [Member]
Quota D [Member]
Quota E [Member]
Consolidated quota [Member]
Equity Method Investment, Nonconsolidated Investee [Axis]
Income Statement Location [Axis]
Research and Development Expense [Member]
General and Administrative Expense [Member]
Third Parties [Member]
Product and Service [Axis]
Consultants and Other Third Parties [Member]
Related Parties [Member]
Materials And Supplies [Member]
Compensation [Member]
Travel And Entertainment [Member]
Other [Member]
Accounting Legal and Other Professional [Member]
Facility and Insurance Related [Member]
San raffaele hospital [Member]
Carlo russo [Member]
Richard Slansky [Member]
San raffaele hospital Osr [Member]
Executive bonus [Member]
Xdg biomed [Member]
Financial consultant [Member]
Investment, Name [Axis]
Spafid SPA [Member]
Pierluigi Paracchi [Member]
Naldini [Member]
Gentner [Member]
XDG Biomed LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
License Agreement Amendment One [Member]
Scenario [Axis]
First Indication [Member]
Second Indication [Member]
Third Indication [Member]
License Agreement Amendment Two [Member]
License Agreement Amendment Three [Member]
First Solid Cancer Indication [Member]
Second Solid Cancer Indication [Member]
License Agreement Amendment Four [Member]
First Solid Cancer Indication Option Fee [Member]
Second solid cancer indication option fee [Member]
License Agreement Amendment Five [Member]
Sponsor Research Agreement [Member]
Investigator [Member]
Data manager [Member]
OSR Operating Leases And Office Rent [Member]
AGC Manufacturing [Member]
Insurance on operating leases [Member]
Lympho hematopoietic [Member]
Legal Entity [Axis]
OSR [Member]
Related Milestone One [Member]
Related Milestone Two [Member]
AGC Biologics Agreement [Member]
AGC Agreement [Member]
Amendment Four [Member]
Amendment Five [Member]
Amendment Six [Member]
Amendment Seven [Member]
GMP Batch [Member]
LVV Batch [Member]
Frame work service agreement [Member]
Service Agreement [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Employees and Directors [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Income Statement [Abstract]
Operating expenses
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (expense)
Other income
Unrealized exchange rate gain
Total other income (expense)
Loss before income taxes
Income taxes benefit (expenses)
Net loss
Net loss and comprehensive loss
Loss per share:
Loss
Loss per share - basic
Weighted average number of shares outstanding - basic
Statement of Financial Position [Abstract]
Assets
Current assets
Cash and cash equivalents
Prepaid expenses and other current assets
Total current assets
Non-current assets
Property and equipment, net
Other non-current asset- related party
Other non-current assets
Total non-current assets
Total assets
Liabilities and stockholders’ equity
Current liabilities
Accounts payable
Accounts payable - related party
Accrued expenses
Accrued expenses - related party
Other current liabilities
Total current liabilities
Non-current liabilities
Other non current liabilities
Retirement benefit obligation
Total long-term liabilities
Commitments and contingencies
Stockholders’ equity
Common stock, no par value, 59,700,000 shares authorized and 18,216,858 shares issued and outstanding
Accumulated deficit
Total stockholders’ equity
Total liabilities and stockholders’ equity
Common stock, par value
Common Stock, shares authorized
Common Stock, shares issued
Common Stock, shares outstanding
Statement [Table]
Statement [Line Items]
Beginning balance, value
Beginning balance, shares
Capital increase from exercise of options on Quota B
Share-based compensation
Quota B repurchased
Corporate capital adjustment from Srl to Spa
Corporate capital adjustment from Srl to Spa, shares
Capital increase related to SpA
Capital increase related to SpA, shares
Conversion adjustment from Srl to SpA
Net loss
Ending balance, value
Ending balance, shares
Statement of Cash Flows [Abstract]
Cash flows from operating activities
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense
Retirement benefit obligation
Share-based compensation
Changes in operating assets and liabilities
Prepaid expenses and other current assets
Other non-current assets
Accounts payable
Accounts payable - related party
Accrued expenses
Accrued expenses - related party
Other current liabilities
Other non current liabilities
Net cash used in operating activities
Cash flows from investing activities
Purchases of property and equipment
Net cash used in investing activities
Cash flows from financing activities
Proceeds from the exercise of stock options
Quota B repurchased
Prepaid offering costs
Net cash provided by financing activities
Net increase (Net decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of business and history
Accounting Policies [Abstract]
Summary of significant accounting policies
Research and Development [Abstract]
Research and development
General And Administrative
General and administrative
Income Tax Disclosure [Abstract]
Income taxes
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid expenses and other current assets
Property, Plant and Equipment [Abstract]
Property and equipment, net
Other non-current assets
Retirement Benefits [Abstract]
Retirement benefit obligation
Equity [Abstract]
Stockholders’ equity
Share-Based Payment Arrangement [Abstract]
Share-based compensation
Related Party Transactions [Abstract]
Related parties
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies
Subsequent Events [Abstract]
Subsequent events
Basis of presentation
Principles of consolidation
Use of estimates
Cash and cash equivalents
Net loss and comprehensive loss
Net loss per share
Foreign currency translation
Emerging growth company status
Fair value measurements
Segment information
Tax credit on investments in research and development
Share-based compensation
Representative warrants
Property and equipment
Impairment of long-lived assets
Recently issued accounting pronouncements
Schedule of cash and cash equivalents
Schedule of prepaid expenses and other current assets
Schedule of property and equipment net
Schedule of other non-current assets
Schedule of company’s capital ownership percentage
Schedule of outstanding stock options
Schedule of share based compensation expenses
Schedule of third party and general and administrative expenses
Schedule of accounts payable to related parties
Schedule of accrued expenses to related parties
Schedule of company obligations by contractual maturity
Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]
Subsidiary, Sale of Stock [Line Items]
Conversion of stock, shares issued
Number of shares issued
Number of ordinary shares subscribed
Number of shares exercised
Common stock, shares, outstanding
Sale of stock, net of listing costs
Net loss
Accumulated deficit
Foreign Currency Transaction Gain (Loss), Unrealized
Cash in bank
Cash in hand & prepaid cards
Total
Property, Plant and Equipment [Table]
Property, Plant and Equipment [Line Items]
Share capital increased
Common stock, shares authorized
Common stock, shares, issued
Number of ordinary shares reserved
Number of options shares outstanding
Antidilutive securities, earnings per share, amount
Foreign exchange gains unrealized
Tax credit on investments in research and development, percentage
Tax credit on investments in research and development, annual amount
Number of shares awarded
Number of shares authorized
Number of shares outstanding, percentage
Share-based payment award, options, number of shares, period increase
Number of shares available for issuance
Number of shares outstanding
Exercisable percentage of warrant
Exercise price, per share
Estimated useful lives
Estimated useful lives, description
Value Added Tax (VAT)
Research and development tax credit
Advances payments to suppliers
Other current assets
Other prepaids
Total
Schedule of Defined Benefit Plans Disclosures [Table]
Defined Benefit Plan Disclosure [Line Items]
Percentage of value added tax
Reimbursement of value added tax
Value added tax receivable
Research and development tax credit
Taxes payable, amount
Research and development expense
Others assets current relate to tax credit
Payment for insurance
Prepayment registration fees
Prepaid expense
Computer
Auto
Furniture and fixtures
Total property and equipment
Less: accumulated depreciation
Property and equipment, net
Depreciation expense
Value Added Tax (VAT)
Research and development tax credit
Total
Other non current assets related party
Deferred compensation for employees deferred compensation for employees
Defined contribution plan, maximum annual contributions per employee, percent
Total
Ownership percentage
Schedule of Equity Method Investments [Table]
Schedule of Equity Method Investments [Line Items]
Common stock, voting rights
Nominal amount
Proceeds from capital funding
Financial fees gross
Financial fees net
Corporate capital, percentage
Proceeds from divestiture of businesses
Stock issued during period value stock options exercised
Repurchased during period value
Proceeds from stock options exercised
Quota per share
Capital units
Stock issued during period value conversion of units
Additional paid in capital
Conversion of stock shares issued
Quota percentage of ownership
Share based compensation
Number of options outstanding, Beginning
Weighted average exercise price outstanding, Beginning
Weighted average remaining contractual term outstanding, Beginning
Aggregate intrinsic value outstanding, Beginning
Number of options exercisable, Beginning
Weighted average exercise price exercisable, Beginning
Aggregate intrinsic value exercisable, Beginning
Number of options granted
Weighted average exercise price granted
Aggregate intrinsic value granted
Number of options vested and exercised
Weighted average exercise price vested and exercised
Aggregate intrinsic value vested and exercised
Number of options outstanding, Ending
Weighted average exercise price outstanding, Ending
Aggregate intrinsic value outstanding, Ending
Number of options exercisable, Ending
Weighted average exercise price exercisable, Ending
Aggregate intrinsic value exercisable, Ending
Number of options granted and immediately vested
Weighted average exercise price granted and immediately vested
Weighted average remaining contractual term granted and immediately vested
Aggregate intrinsic value granted and immediately vested
Number of options cancelled or forfeited
Weighted average exercise price cancelled or forfeited
Aggregate intrinsic value cancelled or forfeited
Weighted Average Remaining Contractual Term exercisable, Ending
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total
Unrecognized expense
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option price per share
Vesting period
Stock Repurchased During Period, Value
Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Stock Issued During Period, Value, Stock Options Exercised
Stock Issued During Period, Shares, Issued for Services
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum
Number of options granted and immediately vested
Vested shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Weighted average fair value of options granted
Option term
Expiration date
Share price
Exercise price
Exchange rate
Expected term to maturity
Risk free interest rate
Volatility rate, percentage
Weighted average of ordinary shares
Schedule of Related Party Transactions, by Related Party [Table]
Related Party Transaction [Line Items]
Total
Total
Total
Total
Equity method investment ownership percentage
Salary and Wage, Officer, Excluding Cost of Good and Service Sold
Annual performance bonus
Salary and Wage, Excluding Cost of Good and Service Sold
Percentage of annual bonus
Accrued Bonuses
Interest expense, related party
Retirement benefit obligation
Annual fee
Prepaid expense
Recurring fees
Employee-related Liabilities
Annual gross salary
Related expense
Other Comprehensive Income (Loss), Tax
Due from Related Parties
Gross annual compensation
Contribution of Property
Upfront fee
Future option fees
Decreased future option fees
Royalty fee percentage
Repayments of Related Party Debt
Costs and Expenses, Related Party
Payments for merger related costs gross
Option fee
Interest expense
Milestone payment
Reduction in option fee
Sponsored research activities
Share-Based Payment
Other Comprehensive Income (Loss), Tax
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total
Payments by period, less than a year
Payments by period, one to three years
Payments by period, four to five years
Payments by period, more than five years
Loss Contingencies [Table]
Loss Contingencies [Line Items]
Potential milestone payments
Debt instrument, periodic payment
Contingent consideration, liability
Loss contingency
Payment for license fee
Contingent payments
Debt Related Commitment Fees and Debt Issuance Costs
Other Expenses
Cumulative manufacturing expense
Technology transfer fee
Production Costs, Period Cost
Production costs percentage
Total commitment amount
Total commitment
Payments for Rent
Lease, Cost
Amortization expenses
Property, Plant and Equipment, Net
Lease current
Non current liabilities
Finance lease
Insurance costs
Outstanding payment insurance
Subsequent Event [Table]
Subsequent Event [Line Items]
Non qualified stock options
Other non-current assets related party.
Accounts payable related party.
Accrued liabilities related party.
Research and development tax credit.
Percentage of value added tax.
Corporate Capital [Member]
Research And Development Expense Related Party [Member]
Corporate capital adjustment from srl to spa.
Corporate capital adjustment from Srl to SPA share.
Quota A [Member]
Quota B [Member]
Quota C [Member]
Quota D [Member]
Quota E [Member]
Nominal amount.
Proceeds from capital funding
Financial fees gross.
Financial fees net.
Corporate capital percentage.
Increase decrease in accounts payable related party.
Increase decrease in accrued liabilities related party.
Prepaid offering costs.
Directors and Officers [Member]
Reimbursement of value added tax.
Italian Revenue Agency [Member]
Net Loss And Comprehensive Loss [Policy Text Block]
Equity Incentive Plan 2021 - 2025 [Member]
Emerging Growth Company Status [Policy Text Block]
Tax Credit on Investments In Research and Development [Policy Text Block].
Representative Warrants [Policy Text Block]
Class of warrant or right exercisable percentage of warrants or rights
Equipment And Furniture [Member]
Electronic Office Equipment [Member]
General And Administrative Disclosure [Text Block]
Consolidated quota [Member]
Share based compensation arrangement by share based payment award options vested and expected to vest granted weighted average exercise price.
Share based compensation arrangement by share based payment award options vested and expected to vest granted aggregate intrinsic value.
Share based compensation arrangement by share based payment award options vested and expected to vest granted number.
Share based compensation arrangement by share based payment award options vested and expected to vest vested and exercised number.
Share based compensation arrangement by share based payment award options vested and expected to vest vested and exercised weighted average exercise price.
Share based compensation arrangement by share based payment award options vested and expected to vest vested and exercised aggregate intrinsic value.
Share based compensation arrangement by share based payment award options vested and expected to vest granted and immediately vested weighted average remaining contractual term 1.
Share based compensation arrangement by share based payment award options vested and expected to vest granted and immediately vested number.
Share based compensation arrangement by share based payment award options vested and expected to vest granted and immediately vested weighted average exercise price.
Share based compensation arrangement by share based payment award options vested and expected to vest granted and immediately vested aggregate intrinsic value.
Share based compensation arrangement by share based payment award options vested and expected to vest cancelled or forfeited number.
Share based compensation arrangement by share based payment award options vested and expected to vest cancelled or forfeited weighted average exercise price.
Share based compensation arrangement by share based payment award options vested and expected to vest cancelled or forfeited aggregate intrinsic value.
Stock option exercise price exchange rate.
Third Parties [Member]
Consultants and Other Third Parties [Member]
Related Parties [Member]
Materials And Supplies [Member]
Compensation [Member]
Travel And Entertainment [Member]
Other [Member]
Accounting Legal and Other Professional [Member]
Facility and Insurance Related [Member]
Schedule of accounts payable to related parties [Table Text Block]
San raffaele hospital [Member]
Carlo russo [Member]
Richard Slansky [Member]
Schedule of accrued expense to related parties [Table Text Block]
San raffaele hospital Osr [Member]
Executive bonus [Member]
Xdg biomed [Member]
Financial consultant [Member]
Spafid SPA [Member]
Pierluigi Paracchi [Member]
Annual performance bonus.
Percentage of annual bonus.
Annual fee.
Naldini [Member]
Gentner [Member]
Recurring fees.
XDG Biomed LLC [Member]
Upfront fee.
License Agreement Amendment One [Member]
Future option fees
First Indication [Member]
Second Indication [Member]
Third Indication [Member]
Royalty fee percentage.
License Agreement Amendment Two [Member]
License Agreement Amendment Three [Member]
Payment for option fee.
First Solid Cancer Indication [Member]
Second Solid Cancer Indication [Member]
License Agreement Amendment Five [Member]
Second solid cancer indication option fee [Member]
Milestone payment.
Sponsor Research Agreement [Member]
Sponsor research activities
Investigator [Member]
Data manager [Member]
OSR Operating Leases And Office Rent [Member]
Payments by period, less than a year
Contractual obligation due in one to third year
AGC Manufacturing [Member]
Insurance on operating leases [Member]
Potential milestone.
Lympho hematopoietic [Member]
Related Milestone One [Member]
Related Milestone Two [Member]
OSR [Member]
AGC Biologics Agreement [Member]
Technology transfer fee.
AGC Agreement [Member]
Amendment Four [Member]
Amendment Five [Member]
Amendment Six [Member]
Amendment Seven [Member]
Production costs percentage.
GMP Batch [Member]
LVV Batch [Member]
Frame work service agreement [Member]
Service Agreement [Member]
Employees and Directors [Member]
Prepayment registration fees.
Research and development tax credit noncurrent.
Quota ownership percentage.
Decreased future option fees.
First Solid Cancer Indication Option Fee [Member]
License Agreement Amendment Four [Member]
Reduction in payment for exercise option fee.
Operating Expenses
Operating Income (Loss)
Nonoperating Income (Expense)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Assets, Current
Assets, Noncurrent
Assets [Default Label]
Liabilities, Current
Liabilities, Noncurrent
Stockholders' Equity Attributable to Parent
Liabilities and Equity
Pension and Other Postretirement Benefits Expense (Reversal of Expense), Noncash
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Other Noncurrent Assets
Increase (Decrease) in Accounts Payable
Increase decrease in accounts payable related party
Increase (Decrease) in Accrued Liabilities
Increase decrease in accrued liabilities related party
Increase (Decrease) in Other Current Liabilities
Increase (Decrease) in Other Noncurrent Liabilities
Net Cash Provided by (Used in) Operating Activities
Payments to Acquire Property, Plant, and Equipment
Net Cash Provided by (Used in) Investing Activities
Payments for Repurchase of Common Stock
PaymentsForPrepaidOfferingCosts
Net Cash Provided by (Used in) Financing Activities
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
Research, Development, and Computer Software Disclosure [Text Block]
GeneralAndAdministrativeDisclosureTextBlock
Other Current Assets [Text Block]
Property, Plant and Equipment Disclosure [Text Block]
Other Assets Disclosure [Text Block]
Retirement Benefits [Text Block]
Stockholders' Equity Note Disclosure [Text Block]
Share-Based Payment Arrangement [Text Block]
Commitments and Contingencies Disclosure [Text Block]
Cash and Cash Equivalents, Policy [Policy Text Block]
Share-Based Payment Arrangement, Forfeiture [Policy Text Block]
Property, Plant and Equipment, Gross
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Depreciation
Value Added Tax Receivable, Noncurrent
ResearchAndDevelopmentTaxCreditNoncurrent
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
Accounts Payable, Related Parties, Current
Accrued Liabilities
Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits
Prepaid Expense
Other Comprehensive Income (Loss), Tax [Default Label]
Contractual Obligation